Abstract | The development of high-throughput DNA sequencing technologies has enabled large-scale characterization of functional antibody repertoires, a new method of understanding protective and pathogenic immune responses. Important parameters to consider when sequencing antibody repertoires include the methodology, the B-cell population and clinical characteristics of the individuals analysed, and the bioinformatic analysis. Although focused sequencing of immunoglobulin heavy chains or complement determining regions can be utilized to monitor particular immune responses and B-cell malignancies, highfidelity analysis of the full-length paired heavy and light chains expressed by individual B cells is critical for characterizing functional antibody repertoires. Bioinformatic identification of clonal antibody families and recombinant expression of representative members produces recombinant antibodies that can be used to identify the antigen targets of functional immune responses and to investigate the mechanisms of their protective or pathogenic functions. Integrated analysis of coexpressed functional genes provides the potential to further pinpoint the most important antibodies and clonal families generated during an immune response. Sequencing antibody repertoires is transforming our understanding of immune responses to autoimmunity, vaccination, infection and cancer. We anticipate that antibody repertoire sequencing will provide nextgeneration biomarkers, diagnostic tools and therapeutic antibodies for a spectrum of diseases, including rheumatic diseases.
Introduction
Antibodies are a major component of the adaptive immune system and have critical roles in protective and pathogenic immune responses. In response to microbial infection, vaccination, autoimmune disease or cancer, the immune system generates distinct antibody reper toires. Analysis of these antibody repertoires, particularly those contributing to functional immune responses, can provide important information on protective and patho genic immunity. In autoimmune diseases, including autoimmune rheumatic diseases, antibody characteriza tion has enabled the identification of autoantigens and has provided insights into the underlying mechanisms of disease; furthermore, detection of auto antibodies has become a cornerstone of modern diagnostics. [1] [2] [3] In infectious diseases, in which antibody responses are usually protective, there is growing interest in isolating anti bodies that could be developed as novel therapeutic agents 4, 5 and in using microbial antigens and epitopes targeted by antibody responses to develop vaccines. 4, 6, 7 A challenge in understanding, as well as in diagnosti cally and therapeutically harnessing, antibody responses is the identification of antibodies that underlie functional immune responses, that is, antibodies that directly con tribute to an immune outcome, such as neutralizing a microbial pathogen or mediating autoimmune tissue injury. This Review provides an overview of technolo gies for largescale sequencing of antibody repertoires, and discusses how these technologies can be applied to characterize immune responses and identify anti bodies of therapeutic, diagnostic or mechanistic relevance to autoimmune diseases, including rheumatic diseases.
Antibody responses
Antibodies are comprised of an immunoglobulin heavy chain (IgH) and light chain (IgL), each contain ing an antigenbinding domain that is generated by the recombination, junctional diversification and somatic hypermutation of variable (V), joining (J) and/or diver sity (D) gene segments during Bcell development. 8, 9 The complementaritydetermining regions (CDRs), CDR1, CDR2 and CDR3, as well as the surrounding framework regions, together form the antigenbinding site of the antibody. 10 In the primary Bcell repertoire, substantial diversity in antibody specificity comes from the IgH CDR3 owing to its generation both from com binatorial gene segments and from Nregion diversity. 10 In an ongoing immune response to an antigen, B cells that produce antibodies specific for that antigen further diversify by undergoing clonal expansion and by somatic hypermutation of their antibody variable regions. In this process, termed affinity maturation, B cells that express antibodies with an increased affinity for the activating antigen as a result of somatic hypermutation are selected for further expansion ( Figure 1 ). [11] [12] [13] These antigenactivated, affinitymatured B cells are then released from germinal centers into the blood as short lived or longlived plasmablasts, which migrate to other secon dary lymphoid organs and sites of tissue injury, and can differentiate into longlived memory B cells and plasma cells. 14, 15 Identifying antigens For most diseases, knowledge of the antigens and epitopes targeted by antibody responses is limited. For example, autoimmune diseases affect 3% of the global population, yet in most of these diseases the pathogenic autoantigens have not been identified. 16 In infectious diseases, most of the critical microbial antigens and epitopes targeted by protective antibody responses are also unidentified, 17 with the exception of HIV antigens, influenza and some other microbes. 18 With regards to cancer, Tcellmediated responses are considered the primary form of immunity. Although immunotherapies are now revolutionizing cancer therapy, 19, 20 the specific targets of the immune response to these therapies are unclear, as is the contribution of antibody responses to effective anticancer immunity.
A variety of 'array and display' approaches have been developed for investigating antibody responses, including pro tein and peptide arrays, 21 aptamer and pep toid arrays, 22 ran dom peptide arrays, 23 largescale pep tide arrays, 24 human protein arrays, 25 and human proteomic display arrays. 26 One major challenge of these approaches is the use of serum or plasma samples as the source of anti bodies analysed. Serum (and plasma) samples contain a pool of all the antibodies produced by an individual, including antibodies that are heterogeneous, bind to many differ ent antigens, and have differing affinities and avidities, thereby increasing background reactivity and diluting potential antibodies of interest. Furthermore, most serum antibodies are produced by plasma cells generated in prior immune responses, and are not produced by the plasma blasts or plasma cells responding to the immunogenic antigen of interest. Another major challenge is that most approaches involve screening the binding of blood antibodies against panels of preselected antigens. For example, important autoantigens in rheumatoid arthritis (RA) are post translationally citrullinated, 27, 28 and in systemic lupus erythematosus (SLE) are posttranslationally cleaved or phosphorylated; 29 therefore, preselecting antigens might result in the failure to detect pathogenic autoantibody clonal families. Antigenagnostic approaches (those that are antigenindependent) are therefore needed for iden tifying important functional antibodies and their targets. An ideal solution is to isolate, recombinantly express, and characterize antibodies produced by the specific subset of B cells participating in functional immune responses to vaccination, infection, cancer or other diseases, in humans or other animals. In this Review, I describe several DNA sequencing approaches that are currently used to achieve this end.
B-cell populations
Selection of Bcell populations is an important consid eration for antibody sequencing. The best B cells for charac terizing the functional antibody repertoire include plasmablasts, plasma cells, memory B cells and tissue infiltrating B cells (Figure 1 ). Of these cells, plasma blasts and memory B cells are the two populations that are present in peripheral blood and are therefore most easily isolated from humans.
Plasmablasts and plasma cells
Plasmablasts and plasma cells are the antibody producing cells of the immune system. During an immune response, plasmablasts differentiate from antigenactivated B cells and are released from germinal centers to transiently cir culate in the bloodstream before migrating to second ary lymphoid organs or to inflamed tissues, where they can differentiate into l ongerlived ti ssueresident plasma cells. [30] [31] [32] Plasmablasts in peripheral blood form not only from newly generated naive B cells, but also from reac tivated memory B cells. Together with the relative ease of isolating plasmablasts, their origin from either naive or memory B cells make them an ideal Bcell popula tion to analyse when searching for antibodies associated with any given immune response. For example, studies sequencing the antibody response to influenza vacci nation have detected a transient increase in peripheral blood plasmablast numbers, >75% of which produced antiinfluenza antibodies. 33, 34 Although autoimmune diseases are chronic, evi dence exists that underlying autoantibody responses involve continuous activation and reactivation of new Bcell clones, 35 such that peripheral blood plasma blasts could produce new pathogenic antibodies at any stage of the disease. Indeed, in patients with RA, the pro portion of plasmablasts in the blood correlates posi tively with disease activity, 27, 36 and these cells produce anti citrullinated protein antibodies (ACPAs) 27, 28 that are known to contribute to the pathology of RA. 37, 38 Tissueresident plasma cells and plasmablasts might also produce ACPAs and might even be generated in situ in the synovial tissue of patients with RA; however, these tissueresident cells are not easily accessible.
39-41
Memory B cells Memory B cells form during germinal centre reactions and provide an accelerated antibody response upon re exposure to a target antigen. 42 Whereas >75% of peripheral blood plasmablasts are specific for the antigens targeted by the ongoing immune response, 33, 34, 43 antigenspecific memory B cells are present at much lower frequencies; approximately 1 of 2,500-100,000 memory B cells in blood are specific for the inciting antigen. 42, 44, 45 These memory B cells can be isolated by antigensorting (by fluorescence activated cell sorting [FACS] , with fluorescentlylabelled antigen baits to sort the cells by the specificity of their membrane immunoglobulins) of memory B cells from peripheral blood; however, because of the low frequency of antigenspecific memory B cells, such sorting requires large numbers of peripheral blood mononuclear cells. The substantial differences in the antigen load, prior expo sure history, route of exposure, and associated immuno stimulatory molecules in different vaccines, microbial infections, and autoimmune diseases influence the mag nitude and properties of antibody responses; modifica tions of the specific Bcell populations analysed and the timing of their isolation might be needed to effectively c haracterize antibody responses in these conditions.
Tissue-infiltrating B cells
Analysis of tissueinfiltrating B cells could also help to characterize functional antibody responses. Despite being more difficult to access than peripheral blood B cells, characterization of tissueinfiltrating B cells in both autoimmune disease 46, 47 and in cancer 48 has iden tified diseaseassociated antibodies. Integrated analysis of the Bcell antibody repertoires in the synovium and blood of patients with RA, and the brain and blood of patients with multiple sclerosis, 46, 47 is providing insights into the sites of Bcell activation and affinity maturation in these diseases.
Small-scale sequencing
An approach used in the 1990s and 2000s for the analy sis of antibody repertoires involves reverse transcriptase poly merase chain reaction (RTPCR) and Sanger sequenc ing of antibodies expressed by individual B cells. Because the experimental steps in this technique require manual handling, in practice this approach can only characterize tens to hundreds of B cells per experiment. Despite low throughput, the technique has been used to identify anti bodies that neutralize clinically important pathogens such as HIV1 and influenzae viruses, 5, 33, [49] [50] [51] [52] or autoantibodies that contribute to autoimmune disease. 46, 53 A variety of approaches have been used for singlecell RNA sequencing, [54] [55] [56] [57] several of which enable sequencing Nature Reviews | Rheumatology 12,13 After multiple rounds of somatic hypermutation and clonal selection, antibody-expressing B cells produce antibodies with increased affinity for their target antigen. 10 B cells that express high-affinity antibodies respond further to growth factors and other signals that induce differentiation into plasmablasts and memory B cells. 11, 14, 15 Plasmablasts transiently circulate in the blood and migrate to secondary lymphoid organs and tissues involved in the disease process, including tissues under autoimmune, infectious or malignant attack. Memory B cells circulate in the blood, and enable rapid recall responses upon re-exposure to their target antigen, whereas plasma cells localize primarily in the bone marrow and lamina propria, where they secrete antibodies. Abbreviations: CDRs, complementarity determining regions; FDC, follicular dendritic cell.
of coexpressed genes and use nextgeneration technol ogy. However, these assay platforms and shortread sequencing technologies, for example, HiSeq™ platforms (Illumina, USA), read considerably fewer base pairs than are necessary (>500) for sequencing the entire IgL and IgH variable regions. 58 
Large-scale sequencing
A variety of highthroughput nextgeneration sequenc ing technologies have now been developed 59, 60 and are transforming the analysis of B cells and their antibody repertoires. 4, 58, [61] [62] [63] These technologies are applied in a variety of ways, and important parameters for charac terization of functional antibody responses include the methodological approach, the Bcell populations charac terized, the clinical characteristics of the individuals a nalysed, the approach to bioinformatic analysis and the objective of the experiment.
Monitoring specific B cells
A number of research groups have developed approaches for deepsequencing IgH (or in some cases the IgL), or solely the CDR3, in genomic DNA or cDNA generated from bulk RNA isolated from individuals with auto immune disease, 47, 64 infections 65 or cancer, 66, 67 or from vaccine recipients. 68 In some instances, molecular 'bar codes' are used to enhance singlechain or CDR3 sequenc ing, for example, use of random hexamers as primers 10, 69, 70 or adapters with unique molecular identifiers 54, 55 to tag each cDNA. Molecular barcoding enables the correction of basecalling errors inherent to the sequencing platform or of PCR bias, although not the correction of RTPCR errors or accurate identification of the clonal proportions of the B cell pool.
Sequencing immunoglobulin genes in genomic DNA is challenging because as many as 50% of B cells have multiple rearranged immunoglobulin gene loci, a result of nonproductive rearrangements and receptor editing. 71, 72 Furthermore, receptor editing, an important feature in Bcell maturation that helps to prevent auto immunity, can lead to allelic inclusion at the immuno globulin IgL loci and the development of B cells that coexpress two different immunoglobulin IgLs, thereby confounding the sequencing of IgH and IgL cDNA from individual B cells. 71, 72 Moreover, although rapid, these methods usually involve the sequencing of only one immunoglobulin chain and, therefore, provide limited information about the antibodies generated during an immune response. Although both IgHs and IgLs can be sequenced simultaneously in bulk mRNA, pairing of the IgH and IgL sequences obtained in this way can only be attempted according to similarities in sequence frequency; 73 this pairing is not always accurate. Without the accurate pairing of the cognate IgHs and IgLs, the information generated about an antibody response is incomplete.
Although not optimal for analysis of antibody reper toires, singlechain sequencing from bulk RNA can be used to track malignant or clonal populations of B cells by detecting their unique IgH, IgL or CDR3 sequences. 74, 75 This method is proving to be powerful for detecting and monitoring the recurrence of Bcell malig nancies and has better sensitivity for detecting residual disease or disease recurrence than flow cytometry or other conventional approaches. 66, 67 IgH CDR3 sequencing is also used in the search for biomarkers of autoimmune diseases and in character izing Bcell responses to infection and vaccination, and to immunomodulation in patients with cancer. Results from bulk IgH sequencing of unsorted B cells sug gest that direct analysis of isolated Bcell subsets might be neces sary for obtaining the most informative data regard ing diseases of immune function. 76 Additional data are needed to assess whether sequencing of a single chain or a singlechain CDR3 will provide biomarkers with clinical utility. 77 The functional antibody repertoire Many challenges must be overcome to understand and identify functional antibody repertoires (Table 1 ). In addition to high throughput analysis, a comprehen sive survey of the Bcell repertoire requires sequences that enable accurate recreation of endogenous, bio informatically selected antibodies, so that their antigen specificity, binding and functional properties can be characterized. To accurately recreate recombinant ver sions of endogenous antibodies, one must sequence and correctly pair the cognate IgHs and IgLs expressed by individual B cells, ensure that the sequencing covers the entire variable regions encoding the CDR1, CDR2, CDR3 and framework regions of both the IgHs and IgLs, and ensure that the sequences are errorfree. 10, 61, 78, 79 High process fidelity and quality are major challenges for the robust analysis of antibody repertoires, and are further discussed in this article. Furthermore, to enable bioinfor matic identification of important functional antibodies, antibody repertoire sequencing must be applied to the appropriate Bcell subsets derived from individuals with an immunological phenotype of interest (Table 1) .
Several new singlecell sequencing methods can pre serve the endogenous pairing of IgHs and IgLs (Figure 2 ). These methods include linkagePCR based, barcode based, beadbased, microwellbased and dropletbased methods, with most approaches integrating more than one of these methods.
Linkage-PCR
A method for physically linking and thereby sequenc ing IgH and IgL pairs from individual B cells is o verlap extensio n, also known as linkage PCR. 80, 81 Several groups have adapted this technique for highthroughput sequenc ing of IgH and IgL pairs. 82, 83 One such method involves depositing single B cells in highdensity microwell plates, capturing their mRNA with oligodT beads, and then using emulsionbased linkage PCR to physically link and amplify IgH and IgL pairs before sequencing their CDR3 regions (Figure 2a) . 82 Integrating longread sequencing technologies, cell barcodes and universal 5' priming into linkagePCRbased approaches creates the potential to yield robust antibody repertoire datasets.
Cell barcoding
In my laboratory, we developed a cellbarcoding method for antibody repertoire sequencing. 27, 34, 43, 84 In this approach, all cDNA generated from each individual B cell is labelled with a unique cell barcode by using a universal 5' adapter ( Figure 2b, Figure 3a) , which is added via the templateswitching activity of reverse tran scriptase, and enables fulllength and unbiased sequenc ing of the antibody variable regions. Because each B cell has multi ple copies of mRNA encoding its IgH and IgL genes, cell barcoding creates consensus IgH and IgL sequences for each cell and thereby enables correction not only of errors inherent to the sequencing platform, but also of those arising from RTPCR (Figure 3b) . Furthermore, cellbarcoding enables accurate calcula tion of Bcell clonal proportions (Figure 3c ), providing errorcorrected sequences of the fulllength V regions of natively paired IgHs and IgLs and enabling direct gene synthesis of the variable regions of the antibodies for recombinant expression. My laboratory has used this approach to understand human plasmablast antibody responses to RA, 27 Staphylococcus aureus infection, 43 and influenza vaccination. 34 Bioinformatic analysis of sequence datasets can be used to generate phylogenetic trees to guide selection and recombinant expression of plasmablast anti bodies, including ACPAs implicated in the pathogenesis of RA, 27 or antibodies that mediate opsonophago cytosis of Staphylococcus aureus 43 or that neutralize influenza. 34 With this method, rapid and comprehensive characterization of antibody responses is possible, as is the generation of affinitymatured, mono clonal human antibodies with high efficiency relative to hybridoma and other classical approaches for generat ing monoclonal anti bodies. Wardemann and colleagues developed a 2D barcode primer matrix PCR that uti lizes distinct sets of barcoded Vgene forward primers and barcoded c onstantregion reverse PCR primers for multiplex cellbased barcoding of singlecellsorted B cells (Figure 2c) . 61, 85 Droplet PCR Several groups are working to develop dropletbased approaches that utilize beads, linkagePCR or barcodes to enable the sequencing of IgH and IgL pairs expressed by individual B cells (Figure 2d) . 61, 83 These techniques offer the potential to increase throughput analysis and reduce costs. Furthermore, droplet PCR, also termed digital PCR, isolates and amplifies individual DNA molecules in emulsion droplets and thereby reduces PCR bias. 86 
Bioinformatic analysis of clonal families
Sampling depth An important requirement of nextgeneration single cell sequencing technologies is that they generate data sets with IgH and IgL pairs from sufficient numbers of B cells to enable bioinformatic generation of phylo genetic trees and the identification of clonal antibody families (Figure 4) . The sampling depth necessary to characterize a functional antibody response depends on the population of B cells analysed. For example, antigen specific memory B cells are present in blood at frequen cies of 1:2,500-100,000 cells; 42 therefore, a relatively large number of cells must be obtained from the blood (or in some cases by leuka pharesis) to isolate memory B cells with a specific antigen specificity, or to identify clonal families of memory B cells. By contrast, plasma blasts produced during an active antibody response have extensive redundancy in clonal families, and a number of groups have reported that >75% of peripheral blood plasmablasts express antibodies specific to the antigenic target of an ongoing immune response. 33, 34, 43, 87 As a result, when sequencing the plasmablast antibody repertoire of an individual with an ongoing functional immune response, analysis of hundreds to thousands of plasma blasts (obtained from as little as 5-15 ml blood, or just 1-3 ml from infants) is sufficient for robustly identifying and characterizing the clonal families. 27, 34, 43 Bioinformatic methods A number of bioinformatics methods have been devel oped for V(D)J gene assignment and antibody repertoire analysis, 88, 89 and clonal families can be defined as B cells that share IgH VJ and IgL VJ usage. In stricter defini tions of clonal families, the IgH VJs and IgL VJs must have identical CDR3 lengths or the amino acid sequences must have a certain degree of homology, suggesting that the B cells that express these antibodies arose from the same B cell progenitor. 90 Clonal families can be generated by expansion of a common progenitor B cell, by inde pendent de novo recombination events, or by convergent evolution of Bcell responses, that is, accumulation of mutations in B cells that express IgH V(D)J and IgL VJ of different genomic origins, resulting in convergence of encoded antibody sequences. 91, 92 Regardless of their particular ontology, B cells that express highaffinity antibodies are able to 'outcompete' other B cells in the germinal centre for antigen and growth factors during affinity maturation, thereby generating clonal fami lies. 14, 15 Crosspatient analysis of antibody repertoires of individuals with a common immune pheno type has proven to be a powerful method of identifying shared IgH V(D)J and IgL VJ that encode anti bodies with func tional activity at an increased frequency, as compared with identification of clonal families alone. 51, 65, 93 Analysis of coexpressed B-cell functional genes An important direction for antibody repertoire sequenc ing is the integration of analysis of coexpressed genes, in Nature Reviews | Rheumatology an approach analogous to the simultaneous sequencing of Tcell receptors and functional genes that demarcate Tcell subsets. 94, 95 Investigators in my laboratory are now simultaneously sequencing the IgH and IgL genes along with a set of functional Bcell subset genes (Figure 3 ), a strategy that will integrate information about functional Bcell subsets into our antibody repertoire data and thereby enhance our ability to identify functional anti bodies. For B cells, coexpressed functional genes include transcription factors and effector molecules indicative of differentiation into plasma cells, memory B cells, long lived plasmablasts or other maturated Bcell subsets. For quantitative analysis of coexpressed functional genes that are indicative of distinct functional Bcell (or Tcell 94 ) subsets, both cellular and molecular barcoding are needed 54, 55 to quantitatively measure the expression of the coding mRNAs in each cell.
Need for high-fidelity high-quality datasets Obtaining largescale, highfidelity and highquality sequencing data is a critical challenge in sequencing anti body repertoires, and is essential for biomarker analysis and for the generation of diagnostic and therapeutic anti bodies. To achieve these ends, accurate determination of Bcell clonal proportions is needed, as is error correction for provision of highfidelity sequences, comprehensive analysis of all variable regions expressed in the chosen Bcell subset for capturing the entire repertoire, and the ability to detect PCR contamination ( Table 1) .
Analysis of clonal proportions
Accurately measuring the size of clonal families is impor tant for estimating the degree to which the immune system has selected and expanded a B cell expressing a particular antibody. Selection by the immune system is indicative of a high affinity of Bcell membrane immuno globulins for cognate antigens, and thereby out competing other B cells for antigen and growth factors in the germinal centre (Figure 1) . In studying the antibody response to influenza vaccination with a cellbarcoding approach (Figure 2b) , investigators in my laboratory found that large clonal families encode antibodies that bind to influenza haemagglutinin with higher affinities, and in certain cases are more effective at neutralizing Nature Reviews | Rheumatology AAA  AAA  AAA  AAA  AAA  AAA  AAA  AAA  AAA   CCC  CCC  CCC  CCC  CCC  CCC  CCC  CCC   GGG  GGG  GGG  GGG  GGG  GGG  GGG influenza virus than antibodies that are not part of large clonal families. 34 PCR bias, in which certain templates amplify more efficiently than other templates, can distort clonal proportions. 96 In addition, activated B cells, such as plasmablasts, express as much as 100fold more RNA than memory B cells and other resting B cells, 97 which, in the absence of cellbased barcoding 27 or amplification of each cell's cDNA within an individual emulsion droplet, 98 might suggest artificial differences in clonal proportions. Analysis of antibodies expressed by individual cells, with cell barcodes 27, 34, 43, 54, 55 ( Figure 3c ) and emulsion droplets, 98 can correct or minimize PCR bias to enable accurate determination of clonal proportions.
Biological variation versus error
Robust analysis of datasets is highly dependent on obtain ing highfidelity, errorfree sequences. Sequence errors arise from both RTPCR and the sequencing platform. 10, 54, 55, 70, 100 or cell barcodes. 27, 34, 43, 54, 55 Cell barcodes pro vide multi ple advantages over molecular barcodes, including error correction of both RTPCR and basecalling sequencing errors as well as accurate assessment of clonal proportions (Table 1, Figure 3) .
Analysis of antibody variable regions
Most approaches for sequencing antibody repertoires use 5' Vgene primers, which fail to amplify variable regions containing V genes encoded by germline sequences with insufficient homology or that have acquired somatic hypermutations in the residues to which such primers hybridize. Indeed, in my laboratory's antibody repertoire analysis of plasmablasts from influenza vaccine recipi ents, 34 we found that ~10% of all antibodies analysed had an IgH or IgL variable region that would not have been amplified by stateoftheart Vgenespecific primers. Capturing such highly mutated antibodies is impor tant because they might have acquired variable region mutations that confer binding and functional activity.
Ability to detect PCR contamination
Most nextgeneration sequencing approaches for anti body repertoire analysis utilize PCR to amplify DNA isolated, or cDNA generated, from B cells. PCR exponen tially amplifies sequences, and is highly prone to contam ination by amplicons from prior experiments. 101 As the sequences isolated by antibody repertoire analysis have a high degree of nucleotide sequence homology, detect ing PCR contamination can be difficult. 27 Both cell and molecule barcodes provide a means to b ioinformatically monitor and detect PCR contamination.
Applications
Generation of recombinant antibodies Monoclonal antibodies are a mainstay of diagnostic tests, therapeutics and research tools. Highthroughput sequencing of antibody repertoires is a powerful new approach to generate recombinant monoclonal antibodies directly from humans or other animals during a functional immune response. Therapeutic monoclonal antibodies have revolutionized care for patients with autoimmune diseases (antiTNF, antiIL6, antiIL1 and antiIL12p40 monoclonal antibodies), infection (antirespiratory syn cytial virus monoclonal antibody) and cancer (antiCD20, antiCTLA4, and antiprogrammeddeath 1 [PD1] monoclonal antibodies). Investigators in my laboratory used barcodeenabled antibody repertoire sequencing (Figure 2b ) of plasmablasts isolated from Staphylococcus aureusinfected humans to generate recombinant anti bodies that bind and mediate killing of the bacteria. (Figure 2b ) of periph eral blood plasmablasts derived from patients with RA to identify sequences encoding autoantibodies that target citrullinated fibrinogen and citrullinated enolase. 27 Others have used IgH (singlechain) sequencing of bulk RNA isolated from synovium of patients with RA to identify dominant clones utilizing the IGHV4-34 gene segment and having CDR3s longer than those of anti bodies expressed by naive B cells. 102 Sequences encoding pathogenic autoantibodies have the potential to be used as predictive biomarkers to identify individuals likely to develop disease, experience an autoimmune disease flare or respond to immunomodulatory therapy. 77 A leading hypothesis is that mucosal sites, including the lung and oral cavity, might be critical in the initiation of ACPA responses that lead to the development of RA. 103 Some antibody repertoire sequencing technologies 27, 34, 43 gen erate sequencing reads that extend sufficiently into the antibody constant region to identify the antibody isotype and subclasses, thereby enabling IgA ACPAexpressing B cells to be pinpointed to gain insight into the poten tial environmental exposures and microbial infections that initiate their production in RA. Finally, these sequences also have the potential to be used as pharma codynamic biomarkers to monitor the response to an immunomodulatory drug, or to expedite clinical devel opment by demonstrating the activity of these drugs in proofofconcept studies. 77 Vaccine development A great need exists for the development of vaccines for a variety of pathogens. Antibody repertoire sequencing is used to identify the microbial antigens and epitopes targeted by effective antimicrobial antibody responses that naturally control infection in humans and other animals, 4, 6, 43, 104, 105 thereby enabling the development of vaccines based on these antigens. In addition, anti body repertoire sequencing is used in clinical proofof concept trials to demonstrate that a candidate vaccine, adjuvant or vaccination regimen can induce protective immune responses. 106 Immunomodulatory drug development Immunomodulatory 'checkpoint inhibitors' are revo lutionizing the care of patients with autoimmune diseases and cancer. Abatacept (CTLA4Ig) blocks CD28mediated activation of T cells and is efficacious in the treatment of RA. 107 In patients with metastatic melanoma and other cancers, ipilimumab (antiCTLA4 antibody) and pembrolizumab (antiPD1 antibody) are therapeutically effective by blocking inhibition of T cells. 19, 20, 108 Antibody repertoire analysis and sequencing provides an approach to monitor and char acterize the immune responses induced by candidate immuno modulatory drugs 109 or vaccines. 110 Checkpoint inhibitor therapy in cancer results in the induction of auto immunity in a subset of patients, and antibody repertoire sequencing has the potential to be used to identify individuals at risk for developing autoimmune disease and to characterize the autoimmune response in individuals that do. 19, 20, 108 B-cell repertoire development By analysing the sequences of antibody repertoires in an individual and comparing them to the sequences of the corresponding germline antibody genes, the lineage development of B cells and evolution of antibody responses can be tracked. 42, 58, 61, 62 Using this analysis, one can model and investigate the evolution of func tional antibody responses in health and disease, reveal mechanisms underlying the development of native Bcell repertoires 111, 112 and the activation, development and trafficking of B cells in immune responses of inter est. 47, 113, 114 My laboratory, and several others, are in the process of utilizing antibody repertoire sequencing to investigate the development of anticitrullinated proteinreactive B cells in RA and antinuclear antigen reactive B cells in SLE. Such studies might identify autoantigens and provide insight into disease initiation and p rogression in these and other diseases.
Antigen and epitope discovery Identification of the critical antigens and epitopes tar geted by functional antibody responses is needed. Most approaches require prior knowledge of the target antigen, which is used for screening vast numbers of hybridomas, B cells or panels of candidate antibodies. 115 Antibody repertoire sequencing, by contrast, does not require such knowledge. When applied to plasmablasts derived from a human or other animal with an immune phenotype of interest, this method enables the bio informatic identification of clonal families of antibodies within a functional Bcell response without having to express or screen the antibodies. Such clonal antibody families define important antigens, as determined by the immune response. Recombinant antibodies generated from plasma blast clonal families can be used to iden tify the antigenic specificity of these cells. Such antigen discovery can uncover not only the targets of antibod ies but also those of T cells, because B cells and T cells coordinate responses against the same macromolecular antigen complexes. 116 Comprehensive datasets gener ated by largescale sequencing of antibody repertoires, in combination with identification of the corresponding antigen targets of important antibodies, is anticipated to enable bioinformatic modelling of antibody-antigen structurebinding relationships that will ultimately lead to antibody variable region sequences being used to predict antibody specificity.
Conclusions
Effective characterization of the antibody repertoire requires highfidelity analysis of the fulllength IgH and IgL pairs expressed by individual B cells, to enable robust bioinformatic analysis of the repertoires and accurate recombinant generation of selected antibodies that can be used to identify target antigens and to investigate the mechanisms of their protective and pathogenic func tions. Technologies that utilize cellbarcodes and analyse fulllength paired IgH and IgL are anticipated to provide the greatest utility in terms of identifying biomarkers and gaining new insights into the pathogenesis of RA, SLE, other autoimmune rheumatic diseases, and other diseases. Antibody repertoire analysis will transform our understanding of immune responses to auto immunity, vaccination, infection and cancer, providing new bio markers and diagnostic tools, and enabling efficient generation of therapeutic antibodies.
